• 1. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 2. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 3. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 4. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 5. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584

Research Brief on 2-Amino-3-bromo-5-chloro-4-methylpyridine (CAS: 1199773-28-8): Recent Advances and Applications in Chemical Biology and Pharmaceutical Research

2-Amino-3-bromo-5-chloro-4-methylpyridine (CAS: 1199773-28-8) is a halogenated pyridine derivative that has garnered significant attention in recent years due to its versatile applications in medicinal chemistry and drug discovery. This compound serves as a key intermediate in the synthesis of various biologically active molecules, particularly in the development of kinase inhibitors and other targeted therapeutics. Recent studies have highlighted its potential in modulating protein-protein interactions and as a scaffold for fragment-based drug design.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 2-Amino-3-bromo-5-chloro-4-methylpyridine as a building block for the development of novel Bruton's tyrosine kinase (BTK) inhibitors. The researchers utilized this compound to create a series of analogs with improved selectivity profiles, addressing the issue of off-target effects commonly observed with current BTK inhibitors. The study reported a 40% increase in binding affinity for the target kinase compared to first-generation inhibitors.

In the field of chemical biology, recent work published in ACS Chemical Biology (2024) has explored the use of 1199773-28-8 as a molecular probe for studying enzyme mechanisms. The compound's unique halogen pattern allows for strategic modifications that enable covalent binding studies with cysteine-rich enzymes. This approach has provided new insights into the allosteric regulation of several metabolic enzymes, opening avenues for the development of novel allosteric inhibitors.

From a synthetic chemistry perspective, advances in the preparation of 2-Amino-3-bromo-5-chloro-4-methylpyridine have been reported in Organic Process Research & Development (2023). The new synthetic route offers improved yields (up to 78%) and reduced environmental impact through the use of greener solvents and catalysts. This development is particularly significant for scaling up production while maintaining the compound's high purity required for pharmaceutical applications.

Recent patent filings (2023-2024) indicate growing commercial interest in derivatives of 1199773-28-8, with several pharmaceutical companies developing proprietary compounds based on this scaffold. The patents highlight applications in oncology, inflammatory diseases, and neurodegenerative disorders, suggesting the compound's broad therapeutic potential. Notably, one patent application describes a novel class of dual JAK/FLT3 inhibitors derived from this pyridine core structure.

Ongoing clinical trials (as of Q2 2024) include two drug candidates that utilize 2-Amino-3-bromo-5-chloro-4-methylpyridine as part of their chemical structure. Phase I results for one candidate targeting resistant forms of leukemia have shown promising safety profiles and preliminary efficacy signals. The other candidate, being developed for autoimmune disorders, has demonstrated superior pharmacokinetic properties compared to existing therapies in preclinical models.

Future research directions for this compound include exploration of its potential in PROTAC (proteolysis targeting chimera) technology and as a component of covalent inhibitor platforms. Several research groups are investigating the incorporation of 1199773-28-8 into bifunctional molecules designed for targeted protein degradation, with early results showing enhanced degradation efficiency for challenging drug targets.

• 1381941-40-7(2-Amino-3-bromo-4-(2-chlorophenyl)pyridine)
• 1381936-79-3(2-Amino-5-bromo-4-(2-chlorophenyl)pyridine)
• 1823917-85-6(5-Bromo-3-chloro-4,6-dimethylpyridin-2-amine)
• 26163-03-1(3-bromo-5-chloro-pyridin-2-amine)
• 1563533-03-8(2-Amino-3,5-dibromo-4-(2-chlorophenyl)pyridine)
• 1563529-76-9(2-Amino-3,5-dibromo-4-(4-chlorophenyl)pyridine)
• 1823953-79-2(2-Pyridinamine, 3-bromo-5-chloro-4-(trifluoromethyl)-)
• 1823905-59-4(3-Bromo-5-chloro-4,6-dimethylpyridin-2-amine)
• 1806055-27-5(2-Amino-3-bromo-5-chloro-4-(difluoromethyl)pyridine)
• 1446182-19-9(5-bromo-3-chloro-4-methylpyridin-2-amine)